{"generic":"Flutamide","drugs":["Eulexin","Flutamide"],"mono":{"0":{"id":"236685-s-0","title":"Generic Names","mono":"Flutamide"},"1":{"id":"236685-s-1","title":"Dosing and Indications","sub":{"0":{"id":"236685-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Carcinoma of prostate, In combination with bilateral orchiectomy:<\/b> 250 mg orally every 8 hours<\/li><li><b>Carcinoma of prostate, Stage B2, C or D2, in combination with an LHRH agonist:<\/b> Stage B2-C: 250 mg ORALLY every 8 hr in conjunction with a luteinizing hormone-releasing hormone (LHRH) agonist; begin 8 weeks prior to initiating radiation therapy and continue during radiation therapy<\/li><li><b>Carcinoma of prostate, Stage B2, C or D2, in combination with an LHRH agonist:<\/b> Stage D2 metastatic: 250 mg ORALLY every 8 hr in conjunction with a LHRH agonist; continue until progression<\/li><li><b>Hirsutism:<\/b> 250 mg ORALLY daily<\/li><\/ul>"},"1":{"id":"236685-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in children"},"3":{"id":"236685-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Carcinoma of prostate, Stage B2, C or D2, in combination with an LHRH agonist<br\/><b>Non-FDA Labeled Indications<\/b><ul><li>Carcinoma of pancreas<\/li><li>Carcinoma of prostate<\/li><li>Carcinoma of prostate, In combination with bilateral orchiectomy<\/li><li>Hirsutism<\/li><li>Hypersecretion of ovarian androgens; Adjunct<\/li><\/ul>"}}},"2":{"id":"236685-s-2","title":"Black Box Warning","mono":"<b>Oral (Capsule)<\/b><br\/>Liver failure has been reported in patients taking flutamide. Evidence of hepatic injury, occurred usually within the first 3 months, and included elevated serum transaminase levels, jaundice, hepatic encephalopathy, and death related to acute hepatic failure. Serum transaminase levels should be measured prior to starting treatment, monthly for the first 4 months of therapy, and periodically thereafter. Flutamide is not recommended in patients whose ALT values exceed twice the upper limit of normal and should be discontinued if the ALT rises above 2 times the upper limit of normal or jaundice occurs during therapy.<br\/>"},"3":{"id":"236685-s-3","title":"Contraindications\/Warnings","sub":[{"id":"236685-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to flutamide or any component of the preparation<\/li><li>severe hepatic impairment; monitor baseline hepatic enzymes before initiating treatment<\/li><\/ul>"},{"id":"236685-s-3-10","title":"Precautions","mono":"<ul><li>aniline toxicity (methemoglobinemia, hemolytic anemia and cholestatic jaundice) have occurred; increased risk with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease and smokers; monitoring required<\/li><li>hepatic injury, including death due to liver failure, has been reported; monitor<\/li><li>pregnancy; may cause fetal harm<\/li><li>women, particularly in nonserious or nonlife-threatening conditions; not recommended<\/li><\/ul>"},{"id":"236685-s-3-11","title":"Pregnancy Category","mono":"D (FDA)<br\/>"},{"id":"236685-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"236685-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Rash<\/li><li><b>Endocrine metabolic:<\/b>Hot sweats<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Nausea<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Anemia (6%), Leukopenia (3%), Thrombocytopenia (1%)<\/li><li><b>Hepatic:<\/b>Hepatotoxicity, Liver failure<\/li><\/ul>"},"6":{"id":"236685-s-6","title":"Drug Name Info","sub":{"0":{"id":"236685-s-6-17","title":"US Trade Names","mono":"Eulexin<br\/>"},"2":{"id":"236685-s-6-19","title":"Class","mono":"Antiandrogen<br\/>"},"3":{"id":"236685-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"236685-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"236685-s-7","title":"Mechanism Of Action","mono":"Flutamide is an acetanilid and nonsteroidal antiandrogen. It inhibits the uptake of androgen and its nuclear binding in target tissues.<br\/>"},"8":{"id":"236685-s-8","title":"Pharmacokinetics","sub":[{"id":"236685-s-8-23","title":"Absorption","mono":"<ul><li>Oral: time to peak concentration, 1.3 h +\/- 0.7 h<\/li><li>Effect of food: none<\/li><\/ul>"},{"id":"236685-s-8-24","title":"Distribution","mono":"Protein binding: 94% to 96% <br\/>"},{"id":"236685-s-8-25","title":"Metabolism","mono":"<ul><li>rapid and extensive<\/li><li>Active metabolites: alpha-hydroxylated derivative (hydroxyflutamide) and 2-amino-5-nitro-4-(trifluoro-methyl)phenol<\/li><\/ul>"},{"id":"236685-s-8-26","title":"Excretion","mono":"<ul><li>Fecal: 4.2%<\/li><li>Renal: majority of dose<\/li><li>Dialyzable: no (hemodialysis)<\/li><\/ul>"},{"id":"236685-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Flutamide: 7.8 h<\/li><li>Hydroxyflutamide: 9.6 h +\/- 2.5 h<\/li><\/ul>"}]},"10":{"id":"236685-s-10","title":"Monitoring","mono":"<ul><li>serum prostate specific antigen<\/li><li>improvement in bone pain<\/li><li>serum transaminases; baseline and monthly for the first 4 months of therapy, and periodically thereafter<\/li><li>liver function tests; at first sign of symptoms suggestive of liver-dysfunction (nausea\/vomiting, abdominal pain, and dark urine)<\/li><li>serum methemoglobin levels, in patients with glucose-6-phosphate dehydrogenase deficiency, hemoglobin M disease, and smokers<\/li><\/ul>"},"11":{"id":"236685-s-11","title":"How Supplied","mono":"<b>Generic<\/b><br\/>Oral Capsule: 125 MG<br\/>"},"13":{"id":"236685-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause hot flashes, diarrhea, nausea, or pancytopenia.<\/li><li>Instruct patient to report signs\/symptoms of hepatic dysfunction or anemia.<\/li><\/ul>"}}}